Submissions
GlyTouCan
Glycan Structure Repository
GlyComb
Glycoconjugate Repository
GlycoPOST
Glycomics MS raw data Repository
UniCarb-DR
Glycomics MS Repository for glycan annotations from GlycoWorkbench
LM-GlycoRepo
Repository for lectin-assisted multimodality data
All Resources
Genes / Proteins / Lipids Glycans / Glycoconjugates Glycomes Pathways / Interactions / Diseases / OrganismsTools
SugarDrawer
GlycanBuilder
Glycan Converters
GlycoMaple
GlycomeAtlas
LM-GlycomeAtlas
GALAXY
MCAW
GlycoSim
GRable
Guidelines
MIRAGE
G25282IW
Summary
- GlyTouCan ID
-
G25282IW
- IUPAC Condensed
- GlcN2,6S2(a1-4)GlcA(b1-4)GlcN2,3,6S3(a1-4)IdoA2S(a1-4)GlcN1Me2,6S2(a1-
- Subsumption Level
- Fully-defined saccharide
- Monoisotopic Mass
- 1506.95
External Links
- PubChem Compound
- PubChem Substance
- The Human Metabolome Database
3D Structures
GlycoShape
Sequence Descriptors
- GlycoCT
-
RES 1b:a-dglc-HEX-1:5 2s:methyl 3s:n-sulfate 4b:a-lido-HEX-1:5|6:a 5s:sulfate 6b:a-dglc-HEX-1:5 7s:n-sulfate 8s:sulfate 9b:b-dglc-HEX-1:5|6:a 10b:a-dglc-HEX-1:5 11s:n-sulfate 12s:sulfate 13s:sulfate 14s:sulfate LIN 1:1o(1+1)2n 2:1d(2+1)3n 3:1o(4+1)4d 4:4o(2+1)5n 5:4o(4+1)6d 6:6d(2+1)7n 7:6o(3+1)8n 8:6o(4+1)9d 9:9o(4+1)10d 10:10d(2+1)11n 11:10o(6+1)12n 12:6o(6+1)13n 13:1o(6+1)14n
- WURCS
- WURCS=2.0/5,5,4/[a2122h-1a_1-5_1*OC_2*NSO/3=O/3=O_6*OSO/3=O/3=O][a2121A-1a_1-5_2*OSO/3=O/3=O][a2122h-1a_1-5_2*NSO/3=O/3=O_3*OSO/3=O/3=O_6*OSO/3=O/3=O][a2122A-1b_1-5][a2122h-1a_1-5_2*NSO/3=O/3=O_6*OSO/3=O/3=O]/1-2-3-4-5/a4-b1_b4-c1_c4-d1_d4-e1
Literature
| PubMed ID | Title | First Author | Publication Date | Source |
|---|---|---|---|---|
| 38030893 | COVID-19 vaccine–induced immune thrombotic thrombocytopenia: pathophysiology and diagnosis | Dorgalaleh A | 2025 Jan |
|
| 39342255 | Effectiveness and safety of rivaroxaban or low-molecular-weight heparin in non-major orthopedic surgery: a meta-analysis of randomized controlled trials | Zhu L | 2024 Sep 28 |
|
| 39337591 | Influence of Anticoagulants and Heparin Contaminants on the Suitability of MMP-9 as a Blood-Derived Biomarker | Küper D | 2024 Sep 20 |
|
| 39283750 | Clinical outcomes of patients receiving long-term fondaparinux for thrombotic antiphospholipid syndrome | Bor B | 2024 Sep 16 |
|
| 39254829 | 2023 European Society of Cardiology guidelines for the management of acute coronary syndromes : Statement of endorsement by the NVVC | Zwart B | 2024 Sep 10 |
|
| 39240728 | Fondaparinux Sodium for Anticoagulant Therapy After Primary Percutaneous Coronary Intervention: A Single-Center Randomized Trial in China | Li YY | 2024 Sep 01 |
|
| 39047307 | Anticoagulants for the treatment of isolated lower limb superficial vein thrombosis a Bayesian network meta-analysis of randomized controlled trials | Bontinis A | 2024 Sep |
|
| 39278695 | Unresolved questions on venous thromboembolic disease. Therapeutic management of superficial vein thrombosis (SVT). Consensus statement of the French Society for Vascular Medicine (SFMV) | Sevestre M | 2024 Sep |
|
| 39482298 | Venous thromboembolism in adolescents and young adults with acute lymphoblastic leukemia treated on a pediatric-inspired regimen | Shimony S | 2024 Oct 31 |
|
| 39473017 | Hemorrhages and risk factors in patients undergoing thromboprophylaxis in a respiratory critical care unit: a secondary data analysis of a cohort study | Lyu WR | 2024 Oct 29 |
|
